Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Kewaunee Scientific Reports Results for Second Quarter

KEQU

STATESVILLE, N.C., Dec. 2, 2014 /PRNewswire/ -- Kewaunee Scientific Corporation (Nasdaq: KEQU) today reported sales and earnings for its second quarter ended October 31, 2014.

Net earnings for the quarter increased 65.8 percent to $1,202,000, or $0.45 per diluted share, from net earnings of $725,000, or $0.28 per diluted share, in the second quarter last year. Earnings for the quarter benefited from higher sales and lower manufacturing and operating costs.

For the six months ended October 31, 2014, net earnings were $2,436,000, or $0.92 per diluted share, an increase of 5.4 percent from net earnings of $2,312,000, or $0.89 per diluted share, in the same period last year.

Sales for the second quarter increased 15.9 percent to $30,258,000 from $26,098,000 in the second quarter last year. Domestic Operations sales increased 7.1 percent to $23,629,000 from sales of $22,061,000 in the second quarter last year. During the quarter, increased project bidding opportunities were experienced in certain geographic areas of the country, although the overall domestic laboratory marketplace remained challenging and pricing very competitive. International Operations sales increased 64.2 percent to $6,629,000 from sales of $4,037,000 in the second quarter last year. The Company continues to identify new international sales opportunities, while further strengthening and expanding Kewaunee's market presence in Asia and the Middle East.

For the six-month period, sales were $60,792,000, a 4.6 percent increase over $58,101,000 in the same period last year. Domestic Operations sales decreased 2.6 percent to $47,877,000 from sales of $49,134,000 in the same period last year, and International Operations sales increased 44.0 percent to $12,915,000 from sales of $8,967,000 in the same period last year.

The order backlog was $84.5 million at October 31, 2014, as compared to $82.7 million at July 31, 2014 and $69.5 million at October 31, 2013.

The Company continues to have a strong balance sheet. Cash on hand was $7.7 million at the end of the second quarter, as compared to $5.9 million at the end of the same period last year.  Short-term borrowings under the Company's bank line of credit were $699,000, as compared to $2.5 million at the end of the same period last year, total bank borrowings were $5.1 million, as compared to $7.5 million, and the debt-to-equity ratio was .15-to-1, as compared to .24-to-1. Working capital was $27.9 million, as compared to $25.0 million at the end of the same period last year.

"I am pleased with our progress during the quarter, both in our domestic and international businesses," commented David M. Rausch, Kewaunee's President and Chief Executive Officer. "We continue to enhance Kewaunee's market position in all of our principal geographic markets, as well as strengthen the Kewaunee brand globally. Our Associates continue to focus on pursuing new sales opportunities and strengthening relationships with customers, laboratory planners, and architects, while continuing to reduce manufacturing and operating costs.

"Looking forward, we expect a good second half and fiscal year 2015 for sales and earnings, with the third quarter being the slowest, as our domestic business has historically been impacted in the third quarter by both the concentration of holidays and the weather which affect construction projects. Our forecasts are based on scheduled ship dates for projects in our current order backlog and our expectations that the softness in the domestic laboratory marketplace will continue its gradual improvement and the international marketplace will remain strong."

Other News
As previously announced, the Company increased its quarterly cash dividend to twelve cents per outstanding share from eleven cents per outstanding share, beginning with the dividend payable in September 2014. Additionally, at the Company's annual meeting of stockholders held in August 2014, stockholders re-elected directors David M. Rausch, David S. Rhind, and John D. Russell for three-year terms.

About Kewaunee Scientific
Founded in 1906, Kewaunee Scientific Corporation is a recognized global leader in the design, manufacture, and installation of laboratory, healthcare, and technical furniture products. Products include steel, wood, and laminate casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, and epoxy resin worksurfaces and sinks.

The Company's corporate headquarters are located in Statesville, North Carolina. Direct sales offices are located in the United States, India, Singapore, and China. Three manufacturing facilities are located in Statesville serving the domestic and international markets, and one manufacturing facility is located in Bangalore, India serving the local and Asian markets. The Company's China headquarters, sales office, and assembly operation are located in Suzhou Industrial Park, China. Kewaunee Scientific's website is located at http://www.kewaunee.com.

This press release contains statements that the Company believes to be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this press release, including statements regarding the Company's future financial condition, results of operations, business operations and business prospects, are forward-looking statements. Words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "predict," "believe" and similar words, expressions and variations of these words and expressions are intended to identify forward-looking statements. All forward-looking statements are subject to important factors, risks, uncertainties and assumptions, including industry and economic conditions that could cause actual results to differ materially from those described in the forward-looking statements. Additional information concerning these factors is contained in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this document. The Company assumes no obligation, and expressly disclaims any obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Kewaunee Scientific Corporation

Consolidated Statements of Operations (Unaudited)

(in thousands, except per share data)














Three months ended


Six months ended




 October 31,


October 31,




2014


2013


2014


2013

Net sales



$    30,258


$    26,098


$    60,792


$    58,101

Cost of products sold


24,436


21,205


48,822


46,632

Gross profit



5,822


4,893


11,970


11,469

Operating expenses


3,950


3,759


8,298


7,903

Operating earnings


1,872


1,134


3,672


3,566

Other income


125


90


251


170

Interest expense


(102)


(72)


(183)


(160)

Earnings before income taxes


1,895


1,152


3,740


3,576

Income tax expense


667


406


1,252


1,213

Net earnings



1,228


746


2,488


2,363

Less: net earnings attributable to









    the noncontrolling interest


26


21


52


51

Net earnings attributable to 









    Kewaunee Scientific Corporation


$      1,202


$         725


$      2,436


$      2,312











Net earnings per share attributable to









    Kewaunee Scientific Corporation stockholders







       Basic



$        0.46


$        0.28


$        0.93


$        0.89

       Diluted



$        0.45


$        0.28


$        0.92


$        0.89











Weighted average number of common









shares outstanding









       Basic



2,626


2,606


2,623


2,601

       Diluted



2,659


2,633


2,655


2,618

 

Kewaunee Scientific Corporation

Condensed Consolidated Balance Sheets

(in thousands)














October 31,


April 30,






2014


2014

Assets





(Unaudited)



Cash and cash equivalents




$      4,863


$      6,248

Restricted Cash




2,869


368

Receivables, less allowances




24,074


23,473

Inventories





12,199


11,938

Prepaid expenses and other current assets




1,868


1,326

    Total Current Assets




45,873


43,353

Net property, plant and equipment




14,933


14,570

Other assets





5,023


4,794

Total Assets





$    65,829


$    62,717









Liabilities and Equity







Short-term borrowings and interest rate swap




$         941


$      3,150

Current portion of long-term debt




421


421

Accounts payable




11,405


8,542

Other current liabilities




5,219


4,050

    Total Current Liabilities




17,986


16,163

Other non-current liabilities




11,751


12,330

    Total Liabilities




29,737


28,493

Noncontrolling interest




274


265

Kewaunee Scientific Corporation equity




35,818


33,959

    Total Equity




36,092


34,224

Total Liabilities and Equity




$    65,829


$    62,717

 

Contact:

D. Michael Parker


704/871-3290

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/kewaunee-scientific-reports-results-for-second-quarter-300003694.html

SOURCE Kewaunee Scientific Corporation